International PR

press release

Title Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding
writer exocobio
date 2020-07-30

Exosome Start-up ExoCoBio Inc. raises $26.7M in Series B Funding

  • ExoCoBio is the 4th largest funded exosome startup in the world

  • ExoCoBio is using the funding to advance its exosome pharmaceutical R&D and cosmeceutical business

 
  SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc.


announced that it recently raised about $27 million in its series B


funding. Top tier Korean investors participated in this round, including


Seven Tree Equity Partners, CSQUARED Global Asset Management,


TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum


Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum


technology Investment.




  Since it was established in January 2017, ExoCoBio has raised about

$46 million accumulatively including series A round in April 2017 of $11

million.


  Series B money will be used to set up GMP-compliant exosome

manufacturing facilities to produce exosome pharmaceuticals, to

attract high quality talents, and to secure additional business

opportunities for commercialization in cosmetics industry.





                                                                                   <BioInformant> 2018.9.26

                                                              URL : https://bioinformant.com/exocobio-series-b/#more-21311

´Ù¿î·Îµå¼ö 0